SCHEMBL15026080

SCHEMBL15026080

COc1ccc(/C=C/c2cc(O)cc(/C=C/c3ccc(O)cc3)c2)cc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 6/20 0.85
CYP1A1 P04798 5/20 0.85
CYP1B1 Q16678 5/20 0.85
KDM4E B2RXH2 5/20 0.85
PTGS1 P23219 4/20 0.85
LMNA P02545 3/20 0.85
ALOX12 P18054 1/20 0.85
ALOX5 P09917 5/20 0.79
TTR P02766 4/20 0.79
NQO2 P16083 4/20 0.76
MEN1 O00255 4/20 0.76
MAPT P10636 4/20 0.76
KMT2A Q03164 4/20 0.76
ABL1 P00519 3/20 0.76
ABCB1 P08183 3/20 0.76
BCR P11274 3/20 0.76
NPC1 O15118 2/20 0.76
GAA P10253 2/20 0.76
RAB9A P51151 2/20 0.76
GFER P55789 2/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Resveratrol 4'-Methyl Ether SCHEMBL563261 0.92 PTGS2 (1.00) PTGS2CYP1A1CYP1B1KDM4EPTGS1
Resveratrol 4'-Methyl Ether SCHEMBL563262 0.92 PTGS2 (1.00) PTGS2CYP1A1CYP1B1KDM4EPTGS1
Resveratrol 4'-Methyl Ether SCHEMBL4732963 0.92 PTGS2 (1.00) PTGS2CYP1A1CYP1B1KDM4EPTGS1
SCHEMBL8396878 0.92 PTGS2 (0.77) PTGS2CYP1A1CYP1B1KDM4EPTGS1
SCHEMBL12567384 0.92 PTGS2 (0.77) PTGS2CYP1A1CYP1B1KDM4EPTGS1
SCHEMBL8396882 0.92 PTGS2 (0.77) PTGS2CYP1A1CYP1B1KDM4EPTGS1
SCHEMBL2516449 0.89 PTGS2 (0.86) PTGS2CYP1A1CYP1B1KDM4EPTGS1
SCHEMBL562336 0.89 CYP1A1 (1.00) PTGS2CYP1A1CYP1B1KDM4EPTGS1
SCHEMBL2516446 0.89 PTGS2 (0.86) PTGS2CYP1A1CYP1B1KDM4EPTGS1
SCHEMBL562335 0.89 CYP1A1 (1.00) PTGS2CYP1A1CYP1B1KDM4EPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130150628-A1 PHARMACEUTICAL COMPOSITION COMPRISING A CURCUMIN DERIVATIVE DIMAURO THOMAS M (US) 2013-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150628-A1 PHARMACEUTICAL COMPOSITION COMPRISING A CURCUMIN DERIVATIVE CPT1A, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCB1 PTGS2 112/4885CYP1A1 219/4885CYP1B1 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.